Asthma is a chronic respiratory condition marked by airway inflammation and hyperresponsiveness, with varying degrees of severity. Although it is generally manageable with appropriate medications and lifestyle modifications, certain episodes can emerge unexpectedly and pose life-threatening challenges. This case report details a 35-year-old woman who had been effectively managing mild intermittent asthma with inhalers and had been symptom-free for over a year. However, she presented at the emergency unit of TH Anuradhapura with a sudden and severe respiratory crisis triggered by the ingestion of diclofenac sodium oral tablets for mechanical neck pain. The rapidity and severity of her deterioration, following a prolonged period of stability, highlighted a critical deviation from her usual asthma control. This acute exacerbation underscores the importance of recognizing medication-induced asthma exacerbations and their potential to escalate into life-threatening situations, which require urgent and vigilant medical intervention.
The literature on near-fatal asthma episodes and rapid-onset acute exacerbations highlights the varied clinical presentations and triggers of severe asthma. These cases contribute to our understanding of the complexities, triggers, management strategies, and outcomes associated with critical asthma phenotypes. This case exemplifies how a routine medication intake can precipitate a severe, life-threatening asthma crisis, emphasizing the need for heightened awareness, prompt recognition, and tailored therapeutic approaches for managing such critical respiratory events.
Sudden and rapid-onset asthma attacks are a crucial but infrequent manifestation of asthma, particularly observed in individuals with a history of Severe Life-Threatening Asthma (SLTA)(1). Our patient had a history of mild intermittent asthma but had been well-controlled without inhalers for over a year. Evidence suggests that Rapid Onset Acute Asthma (ROAA) is a rare but distinct presentation in emergency departments (ED), often more common in male patients. Although various triggers are recognized, Upper Respiratory Tract Infections (URTIs) are not typically significant in these cases. ROAA patients generally experience a rapid decline followed by a quicker response to treatment, resulting in lower hospital admission rates compared to those with Slow Onset Acute Asthma (SOAA)(2). In this case, the only identified trigger was the oral diclofenac sodium tablet taken 15–30 minutes prior for neck pain, with no other triggers found after thorough evaluation.
Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), is commonly prescribed to alleviate pain, inflammation, and swelling. It inhibits substances that cause these effects and is available in various forms, including tablets and topical applications. NSAIDs can induce severe asthma through the inhibition of cyclooxygenase-1 (COX-1), leading to increased release of cysteinyl leukotrienes (Cys-LTs) [3][4]. This pathway results in lower production of prostaglandin E2 (PGE2) due to down-regulation of cyclooxygenase-2 (COX-2), alongside increased expression of leukotriene C4 synthase in bronchial inflammatory cells. Aspirin and NSAIDs further elevate cysteinyl leukotriene synthesis, which, along with genetic factors and receptor overexpression, enhances the inflammatory response [5]. Understanding the pathogenesis of NSAID-induced asthma could improve treatment strategies. Although fatal asthma from oral diclofenac is extremely rare, the occurrence in this case is notable.
While oral diclofenac is not commonly reported as a trigger for near-fatal asthma, there have been rare instances of severe reactions. Reports include fatal anaphylactic reactions to oral diclofenac [6] and acute asthmatic attacks from diclofenac sodium eye drops [8]. This case appears to be unique in demonstrating oral diclofenac sodium as a trigger for rapid-onset near-fatal asthma.
In managing this patient, non-invasive ventilation (NIV) with BiPAP was employed due to hypercarbia and low GCS, aiming to avoid intubation and its associated complications. The management of near-fatal asthma involves a comprehensive approach, including optimizing asthma control, addressing adherence and socioeconomic issues, and recognizing the limitations of pharmacotherapy [10]. Early and aggressive treatment is crucial to maintain oxygenation, relieve airflow obstruction, and reduce airway edema and mucus plugging [11]. Emergency physicians must consider potential complications in severe asthma management [12]. Patient education on asthma as a chronic condition and adherence to treatment is vital [13].
NIV has been explored as a treatment for near-fatal asthma. Studies suggest that NIV may reduce the need for endotracheal intubation and improve outcomes compared to invasive mechanical ventilation (IMV) [14]. NIV has been shown to be safe and effective in patients with severe respiratory acidosis or altered mental status [15]. However, its use in severe acute asthma remains controversial, lacking specific randomized controlled trials or national guidelines [16]. Further research is needed to define the optimal application of NIV in near-fatal asthma cases. The limited evidence and variability in critical asthma care practices highlight the need for additional research to establish the best care strategies for near-fatal asthma [17].